Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.

Conditions

• Grade 3b Follicular Lymphoma
• Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL
• Recurrent Classic Hodgkin Lymphoma
• Recurrent Diffuse Large B-Cell Lymphoma
• Recurrent Follicular Lymphoma
• Recurrent Grade 1 Follicular Lymphoma
• Recurrent Grade 2 Follicular Lymphoma
• Recurrent Grade 3a Follicular Lymphoma
• Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
• Recurrent Transformed Non-Hodgkin Lymphoma
• Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between DLBCL and Classic HL
• Refractory Classic Hodgkin Lymphoma
• Refractory Diffuse Large B-Cell Lymphoma
• Refractory Follicular Lymphoma
• Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
• Refractory Transformed Non-Hodgkin Lymphoma

Interventions

• OTHER: Laboratory Biomarker Analysis
• BIOLOGICAL: Pembrolizumab
• DRUG: Vorinostat

Sponsor

City of Hope Medical Center

Collaborators

• [object Object]